{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=etanercept+%28Enbrel%29",
    "query": {
      "intervention": "etanercept (Enbrel)"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 167,
    "total_pages": 17,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=etanercept+%28Enbrel%29&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-27T09:46:07.394Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00797784",
      "title": "The Safety and Efficacy of Etanercept (Enbrel®) for the Treatment of Discoid Lupus Erythematosus",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Discoid Lupus Erythematosus (DLE)"
      ],
      "interventions": [
        {
          "name": "etanercept(Enbrel®)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Florida Academic Dermatology Centers",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2008-10",
      "completion_date": "2011-04",
      "has_results": false,
      "last_update_posted_date": "2010-05-26",
      "last_synced_at": "2026-09-27T09:46:07.394Z",
      "location_count": 1,
      "location_summary": "Miami, Florida",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00797784"
    },
    {
      "nct_id": "NCT02464878",
      "title": "Multicenter Trial of the Effect of AAT on Islet Transplant Engraftment and Durability After Renal Transplant",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Transplant",
        "Type 1 Diabetes"
      ],
      "interventions": [
        {
          "name": "Alpha 1-Antitrypsin",
          "type": "DRUG"
        },
        {
          "name": "Islet Transplantation",
          "type": "PROCEDURE"
        },
        {
          "name": "Thymoglobulin",
          "type": "DRUG"
        },
        {
          "name": "Basiliximab",
          "type": "DRUG"
        },
        {
          "name": "Etanercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Massachusetts General Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 2,
      "start_date": "2017-01",
      "completion_date": "2022-12",
      "has_results": true,
      "last_update_posted_date": "2023-12-22",
      "last_synced_at": "2026-09-27T09:46:07.394Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02464878"
    },
    {
      "nct_id": "NCT02112097",
      "title": "ASIS for Enbrel in Plaque Psoriasis",
      "overall_status": "UNKNOWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Plaque Psoriasis."
      ],
      "interventions": [
        {
          "name": "Gadolinium",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Enbrel subcutaneously at Week 12",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Enbrel subcutaneously at Week 24",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Enbrel subcutaneously at Week 36",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Enbrel subdermally at Week 12",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Enbrel subdermally at Week 24",
          "type": "DRUG"
        },
        {
          "name": "Efficacy of Enbrel subdermally at Week 36",
          "type": "DRUG"
        },
        {
          "name": "PASI 75 n(%) subcutaneously at Week 12",
          "type": "DRUG"
        },
        {
          "name": "PASI 75 n(%) subcutaneously at Week 24",
          "type": "DRUG"
        },
        {
          "name": "PASI 75 n(%) subcutaneously at Week 36",
          "type": "DRUG"
        },
        {
          "name": "PASI 75 n(%) subdermally at Week 12",
          "type": "DRUG"
        },
        {
          "name": "PASI 75 n(%) subdermally at Week 24",
          "type": "DRUG"
        },
        {
          "name": "PASI 75 n(%) subdermally at Week 36",
          "type": "DRUG"
        },
        {
          "name": "Adverse Reactions of Enbrel subcutaneously",
          "type": "DRUG"
        },
        {
          "name": "Adverse Reactions of Enbrel subdermally at Week 36",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ASIS Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 60,
      "start_date": "2016-01",
      "completion_date": "2017-06",
      "has_results": false,
      "last_update_posted_date": "2015-06-24",
      "last_synced_at": "2026-09-27T09:46:07.394Z",
      "location_count": 1,
      "location_summary": "Westminster, California",
      "locations": [
        {
          "city": "Westminster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02112097"
    },
    {
      "nct_id": "NCT00585650",
      "title": "Study of Tumor Necrosis Factor Receptor Fusion Protein Etanercept (Enbrel) in Psoriasis of the Hands and/or Feet",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Etanercept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo injections",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "University of California, Irvine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 20,
      "start_date": "2007-05",
      "completion_date": "2008-05",
      "has_results": true,
      "last_update_posted_date": "2023-08-18",
      "last_synced_at": "2026-09-27T09:46:07.394Z",
      "location_count": 3,
      "location_summary": "Irvine, California • Winston-Salem, North Carolina • Seattle, Washington",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Winston-Salem",
          "state": "North Carolina"
        },
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00585650"
    },
    {
      "nct_id": "NCT00201812",
      "title": "Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tumors"
      ],
      "interventions": [
        {
          "name": "Etanercept",
          "type": "DRUG"
        },
        {
          "name": "Docetaxel",
          "type": "DRUG"
        },
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ohio State University Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2000-11",
      "completion_date": "2005-05",
      "has_results": false,
      "last_update_posted_date": "2017-12-06",
      "last_synced_at": "2026-09-27T09:46:07.394Z",
      "location_count": 1,
      "location_summary": "Columbus, Ohio",
      "locations": [
        {
          "city": "Columbus",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00201812"
    },
    {
      "nct_id": "NCT00509600",
      "title": "Etanercept (Enbrel) for Juvenile Myelomonocytic Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Leukemia"
      ],
      "interventions": [
        {
          "name": "Etanercept",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "M.D. Anderson Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "18 Years",
        "sex": "ALL",
        "summary": "6 Months to 18 Years"
      },
      "enrollment_count": 1,
      "start_date": "2004-09",
      "completion_date": "2009-04",
      "has_results": true,
      "last_update_posted_date": "2012-08-07",
      "last_synced_at": "2026-09-27T09:46:07.394Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00509600"
    },
    {
      "nct_id": "NCT04066348",
      "title": "TNF-α Treatment of Blast-Induced Tinnitus",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Tinnitus, Noise Induced"
      ],
      "interventions": [
        {
          "name": "Etanercept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Saline",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "OTHER"
      ],
      "sponsor": "Wayne State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 88,
      "start_date": "2022-07-01",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2026-02-23",
      "last_synced_at": "2026-09-27T09:46:07.394Z",
      "location_count": 4,
      "location_summary": "Celebration, Florida • Coral Gables, Florida • Detroit, Michigan + 1 more",
      "locations": [
        {
          "city": "Celebration",
          "state": "Florida"
        },
        {
          "city": "Coral Gables",
          "state": "Florida"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Farmington Hills",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04066348"
    },
    {
      "nct_id": "NCT01597245",
      "title": "A Phase 3 Study in Participants With Moderate to Severe Psoriasis (UNCOVER-2)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "80 mg ixekizumab Dosing Regimen",
          "type": "DRUG"
        },
        {
          "name": "50 mg etanercept",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eli Lilly and Company",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 1224,
      "start_date": "2012-05-18",
      "completion_date": "2019-06-18",
      "has_results": true,
      "last_update_posted_date": "2020-06-26",
      "last_synced_at": "2026-09-27T09:46:07.394Z",
      "location_count": 41,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Little Rock, Arkansas + 38 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01597245"
    },
    {
      "nct_id": "NCT00733096",
      "title": "A 3-arm Multi-center, Randomized Controlled Study Comparing Transforaminal Corticosteroid, Transforaminal Etanercept and Transforaminal Saline for Lumbosacral Radiculopathy",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "Lumbosacral Radiculopathy"
      ],
      "interventions": [
        {
          "name": "etanercept",
          "type": "DRUG"
        },
        {
          "name": "methylprednisolone",
          "type": "DRUG"
        },
        {
          "name": "normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Johns Hopkins University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "18 Years to 70 Years"
      },
      "enrollment_count": 84,
      "start_date": "2008-08",
      "completion_date": "2011-03",
      "has_results": true,
      "last_update_posted_date": "2012-10-08",
      "last_synced_at": "2026-09-27T09:46:07.394Z",
      "location_count": 2,
      "location_summary": "Washington D.C., District of Columbia • Fort Bragg, North Carolina",
      "locations": [
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Fort Bragg",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00733096"
    },
    {
      "nct_id": "NCT05080218",
      "title": "COVID-19 VaccinE Response in Rheumatology Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Rheumatoid Arthritis",
        "Psoriatic Arthritis",
        "Spondylarthritis"
      ],
      "interventions": [
        {
          "name": "Upadacitinib",
          "type": "DRUG"
        },
        {
          "name": "Abatacept",
          "type": "DRUG"
        },
        {
          "name": "Secukinumab",
          "type": "DRUG"
        },
        {
          "name": "Tofacitinib",
          "type": "DRUG"
        },
        {
          "name": "TNF Inhibitor",
          "type": "DRUG"
        },
        {
          "name": "Canakinumab Injection",
          "type": "DRUG"
        },
        {
          "name": "Baricitinib",
          "type": "DRUG"
        },
        {
          "name": "Ixekizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jeffrey Curtis",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 841,
      "start_date": "2021-11-15",
      "completion_date": "2024-05-28",
      "has_results": false,
      "last_update_posted_date": "2025-05-02",
      "last_synced_at": "2026-09-27T09:46:07.394Z",
      "location_count": 8,
      "location_summary": "Birmingham, Alabama • Hoover, Alabama • Phoenix, Arizona + 4 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Hoover",
          "state": "Alabama"
        },
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05080218"
    }
  ]
}